Kiniksa Pharmaceuticals International, plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sanj K. Patel
- Full Time Employees
- 366
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 105 Piccadilly London GL United Kingdom W1J 7NJ
- IPO Date
- May 24, 2018
- CIK
- 0001730430
- Website
- kiniksa.com
- Similar Companies
- Business
- Kiniksa Pharmaceuticals International, plc (KNSA) is a commercial-stage biopharmaceutical company that discovers, acquires, develops and commercializes therapeutic medicines for patients with debilitating diseases featuring significant unmet medical needs, with a primary focus on cardiovascular and inflammatory indications worldwide. The company markets ARCALYST (rilonacept), an interleukin-1 alpha and beta inhibitor approved for treating recurrent pericarditis, an inflammatory cardiovascular disease; its pipeline includes vixarelimab, a monoclonal antibody in Phase 2b trials for chronic inducible urticaria and other pruritic skin diseases; KPL-387, a preclinical Fc-modified immunoglobulin G2 monoclonal antibody that received FDA Orphan Drug Designation for pericarditis; and other early-stage candidates targeting unmet needs in immunology and beyond. Founded in 2015 and headquartered in London, United Kingdom, with primary U.S. operations in Lexington, Massachusetts, the company maintains additional facilities in Zug, Switzerland, and La Jolla, California, supporting global development and commercialization efforts. In June 2024, Kiniksa Pharmaceuticals, Ltd. changed its name to Kiniksa Pharmaceuticals International, plc to reflect its expanded international presence; recent highlights include robust ARCALYST net product revenue growth of 61% year-over-year to $180.9 million in Q3 2025, raised full-year 2025 sales guidance to $560-$580 million, a return to profitability with $18.4 million net income in Q3 2025, and pipeline advancement via FDA Orphan Drug Designation for KPL-387 in pericarditis.
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
Grab These 4 Stocks With Solid Net Profit Margins to Maximize Returns
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
Is Kiniksa Pharmaceuticals International PLC (KNSA) Overvalued After 3.5% Rally? GF Value Says Overvalued
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
New Strong Buy Stocks for June 18th
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation
Breakfast News: Enphase Dips As Solar Demand Dims
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution